• Define and execute the long term strategy and vision roadmap• Define and manage the R&D/I landscape • Establish R&D/I partnerships • Ensure consistent best practices, processes, and procedures for R&D/I • Support the development of potential use cases and business models• Budget planning, management and coordination https://orcid.org/0000-0002-6310-4785

- scientific, administrative and financial coordination and management of pharma research and development projects - leading knowledge management to consult the customers and project partners - advising advanced methods/formulations/desings for developing innovative pharma products as well as for optimisation and adaptation of their processes at industrially relevant environment e.g. GMP compliance- leading and planning the company's strategic research framework - acquisition and management of funded and customer projects- Directly reporting to CSO & CEO

- Directly reporting to CSO & CEO, - Monitoring the pharma landscape and its progress to build up R&D pipeline, - In charge of new business strategies to get instant business progress,- acquisition and management of customer and third party funded projectshttps://www.researchgate.net/profile/Nazende-Guenday-Tuereli

Nanoformulations for pharmaceuticals and their advance characterizationSelected publications and communications:* 14th Scientific Meeting, Cystic Fibrosis Basic Research, Waldthausen, “Antibiotic-free nanotherapeutics: Ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.” Invited speaker, 2014*N. Günday Türeli, A.E. Türeli, M. Schneider, Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas aeruginosa Infection in Cystic Fibrosis–A Review, Drug Delivery Letters, 2014, Vol.4, No3*CRS Annual Meeting 2014, A New Strategy to Enhance Antibiotic Load for Pulmonary Treatment of Cystic Fibrosis Infections: Ciprofloxacin Lipid Complex Loaded PLGA NPs (Podium Presentation)*Medi-WING 2014, Development, Demonstration and Clinical Proof of Concept of Nanoparticulate Drug Delivery Systems for Treatment of Chronic P. aeruginosa Infections in Cystic Fibrosis (Poster Presentation)*CRS Local Chapter Meeting 2014, Antibiotic Lipid Nanoformulations against Cystic Fibrosis Infections (Podium Presentation)*10th International Conference and Workshop on Biological Barriers 2014, Günday Türeli,N. et al., Ciprofloxacin-Lipid Complex for Enhanced Drug Loading in PLGA NPs for Pulmonary Treatment of P. aeruginosa Infections in Cystic Fibrosis (Best Poster Award)*AAPS Annual Meeting and Exposition 2013, N. Günday Türeli et al., Ciprofloxacin Complex Encapsulated in PLGA NPs for Pulmonary Treatment of P. aeruginosa Infections in Cystic Fibrosis (Poster presentation)*3rd International HIPS Symposium 2013, Günday Türeli, N. et al., Ciprofloxacin complex formation for encapsulation in PLGA for pulmonary treatment in Cystic Fibrosis (Poster presentation)*N.Günday, M. Schneider, Conference Scene: Nanomedicine and nanotechnology: future prospects and the need for translational factors for the combination of both, Nanomedicine, 2012, 7(6), 811-814

In-vitro drug permetation characterization through biological barriers Bioanalytical method development and validation by HPLC-UV, HPLC-MS/MS17-18.09.2009 Membrane transporters: In vitro models for the study of their role in drug fate, Saarbrücken/GermanyAnalytics of in vitro samples in Memtrans [EU project: LHSB-CT-2006-518246] - Cocktail approach - Oral presentation28.06 – 02.07/2009 34th International Symposium on High-Performance Liquid Phase Separations and Related Techniques, HPLC2009 Dresden/GermanyUtilization of Sample Pooling Technique: Simultaneous Quantification of Multiple Substances - [EU project: LHSB-CT-2006-518246] Main author (Poster presentation)Guenday N. et al., Utilization of Sample Pooling Technique: Simultaneous Quantification of Multiple Substances, 2009, ALTEX 26, Spec.Issue, p.119 7-8/06/2009 2nd PharmSciFair 2009 Nice/FranceComparison of Transport Across Human Carcinoma Cells with Madin-Darby Canine Kidney Cells Transfected with MDR1 gene [EU project: LHSB-CT-2006-518246] Main author (Poster presentation)7-8/06/2009 2nd PharmSciFair 2009 Nice/France Prevalidation of In- vitro Models for Prediction of Secretion Processes at Intestinal Level [EU project: LHSB-CT-2006-518246] Co-author (Poster Presentation)25-26/04/2009 Neurex-SEISC Meeting: Blood Brain Interfaces Strasbourg/FranceValidation of Caco-2 Cell Culture Model for Drug-Drug InteractionsMain author [EU project: LHSB-CT-2006-518246] (Poster presentation)

•Pre-formulation and generic drug formulations for BA/BE studies.•Lab scale and Pilot scale production.•Analytical method validations of generic drugs by LC-UV-(MS), GC.•Drug file submission documentation.•CTD of applied generic drugs for Turkish Health Ministry.•Responses to the scientific and technical questions from the Authority.•Assistance for initiation of Pharmaceuticals National Technology Platform